Science & Innovation
February 1, 2019 | Oncology Central
The National Institute for Health and Care Excellence (NICE) has approved Novartis’ CAR-T therapy Kymriah® (tisagenlecleucel) for the treatment of diffuse large B-cell lymphoma in adults, following a commercial agreement with NHS England.
January 26, 2019 | Oncology Central
Cancer advancements 2018–2019
During 2018 immuno-oncology once again was an immensely popular hot topic. At both the American Association for Cancer Research Annual Meeting 2018 (AACR, April 14–18, IL, USA) and the American Society of Clinical Oncology Annual Meeting (ASCO, 1–5 June 2018, IL, USA) several key studies were presented, which highlighted high success rates with novel immuno-oncology combinations.
Immunotherapy experts discuss the latest cancer immunotherapy advances featured the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
– combination immunotherapy
– biomarker development
– CAR T cell therapies
– new approaches to immune-based cancer treatment.
Panelists include Charles G. Drake, M.D., Ph.D., of New York-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O’Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates.
Video and information source: Cancer Resource Institute